

RESEARCH ARTICLE

Open Access

Cancer suspicion in general practice, urgent referral and time to diagnosis: a population-based GP survey and registry study

Henry Jensen^{1,2*}, Marie Louise Tørring¹, Frede Olesen¹, Jens Overgaard³ and Peter Vedsted¹

Abstract

Background: Many countries have implemented standardised cancer patient pathways (CPPs) to ensure fast diagnosis of patients suspected of having cancer. Yet, studies are sparse on the impact of such CPPs, and few have distinguished between referral routes. For incident cancer patients, we aimed to determine how often GPs suspected cancer at the time of first presentation of symptoms in general practice and to describe the routes of referral for further investigation. In addition, we aimed to analyse if the GP's suspicion of cancer could predict the choice of referral to a CPP. Finally, we aimed to analyse associations between not only cancer suspicion and time to cancer diagnosis, but also between choice of referral route and time to cancer diagnosis.

Methods: We conducted a population-based, cross-sectional study of incident cancer patients in Denmark who had attended general practice prior to their diagnosis of cancer. Data were collected from GP questionnaires and national registers. We estimated the patients' chance of being referred to a CPP (prevalence ratio (PR)) using Poisson regression. Associations between the GP's symptom interpretation, use of CPP and time to diagnosis were estimated using quantile regression.

Results: 5,581 questionnaires were returned (response rate: 73.8%). A GP was involved in diagnosing the cancer in 4,101 (73.5%) cases (3,823 cases analysed). In 48.2% of these cases, the GP interpreted the patient's symptoms as 'alarm' symptoms suggestive of cancer. The GP used CPPs in 1,426 (37.3%) cases. Patients, who had symptoms interpreted as 'vague' had a lower chance of being referred to a CPP than when interpreted as 'alarm' symptoms (PR = 0.53 (95%CI: 0.48;0.60)). Patients with 'vague' symptoms had a 34 (95% CI: 28;41) days longer median time to diagnosis than patients with 'alarm' symptoms.

Conclusions: GPs suspect cancer more often than they initiate a CPP, and patients were less likely to be referred to a CPP when their symptoms were not interpreted as alarm symptoms of cancer. The GP's choice of referral route was a strong predictor of the duration of the diagnostic interval, but the GP's symptom interpretation was approximately twice as strong an indicator of a longer diagnostic interval.

Keywords: Fast-track, Neoplasm, (Early) diagnosis, General practice, Delay, Cancer suspicion, Denmark

* Correspondence: henry.jensen@feap.dk

¹Research Unit for General Practice, Research Centre for Cancer Diagnosis in Primary Care, Department of Public Health, Aarhus University, Bartholins Allé 2, DK-8000 Aarhus C, Denmark

²Section for General Medical Practice, Department of Public Health, Aarhus University, Bartholins Allé 2, DK-8000 Aarhus C, Denmark

Full list of author information is available at the end of the article

Background

Standardised cancer patient pathways (CPPs) have been implemented during the last decade in many countries, including Denmark, to ensure fast diagnosis of patients suspected to have cancer. This strategy is intended to improve patient satisfaction, reduce waiting times and ensure earlier and faster diagnosis, which should ultimately improve the patient's prognosis [1-7]. Even though the contents of the CPPs differ between countries, all CPPs operate with criteria-based suspicion of cancer and a guaranteed timeframe.

The UK have introduced two-week wait referrals (2WW): referrals where the GP suspects cancer and refers the patient as urgent, meaning the patient should be seen by a specialist within two weeks. To qualify to be referred as urgent to a 2WW, the patient need to fulfil the criteria outlined in the NICE guidelines. Previous studies of the British 2WW referrals have shown that the general practitioners' (GPs) use of these referrals was from one in five to one in three of cancer patients and that patients not referred urgently had significantly longer duration of the time to diagnosis [8-13].

In 2007–2009, CPPs were introduced in Denmark for diagnosis and treatment of suspected cancer as part of the Danish National Cancer Plan II [2,14]. The Danish CPPs consisted of guidelines, descriptions of selected alarm symptoms that may raise cancer suspicion and well-defined diagnosing schedules from clinical suspicion of cancer until treatment, including specific time frames; hence the Danish CPPs can be seen as comparable to the 2WW in the UK. The five Danish regions (i.e. the hospital owners) were given three months to implement the guidelines at local level [2]. By spring 2009, CPPs for 32 specific cancers had been developed [2,3].

A key issue for assessment of CPPs is knowledge about the decisions behind the timing of CPP initiation for a particular patient. Danish GPs can refer patients to a CPP when a so-called 'reasonable suspicion of cancer' is raised. This suspicion rests on a combination of evidence and consensus regarding the possibility of having cancer when presenting a specific alarm symptom of cancer in combination with preliminary test results for certain age groups [2]. Traditionally, 'alarm' symptoms and signs of cancer have been derived from cancer patients symptomatology when the diagnosis has been established, but many symptoms of cancer are both benign and highly prevalent in the general population and are often presented in general practice [15,16]. This may raise concerns as to whether the GP is able to raise a suspicion of cancer based upon the patient's symptoms. Furthermore, it is unknown if the GP may decide to refer to fast-track diagnosis without 'alarm' symptoms or not. Most previous studies have focused solely on cancer patients with at least one recorded alarm symptom of cancer [17,18]

even though many cancer patients do not present alarm symptoms [19,20]. Consequently, we need more knowledge on how GPs interpret the symptomatology of the full range of cancer patients and who the GP chooses to refer to a CPP. In addition, we need to know more about the GP's handling of cancer suspicion and how this may influence the time to diagnosis.

For these reasons we hypothesized, that when the GPs' suspected cancer based upon the patient's symptoms the GP would be more likely to use a CPP than when the GP did not suspect cancer. Furthermore we suspected that this would influence the duration of the diagnostic interval by longer diagnostic intervals for those patients, where the GP did not suspect cancer and also for those patients not referred to a CPP.

For incident cancer patients, we aimed to determine how often GPs suspected cancer at the time of first presentation of symptoms in general practice and to describe the routes of referral for further investigation. In addition, we aimed to analyse if the GP's suspicion of cancer could predict the choice of referral to a CPP. Finally, we aimed to analyse associations between not only cancer suspicion and time to cancer diagnosis, but also between choice of referral route and time to cancer diagnosis.

Methods


We conducted a population-based cross-sectional study of incident cancer patients who attended Danish general practice prior to the cancer diagnosis.

Setting

Denmark has a population of approximately 5.6 million people and an annual cancer incidence rate of 326 per 100,000 [21]. All citizens in Denmark have free access to diagnosis and treatment services through the publicly funded health-care system. Around 98% of all Danish citizens are listed with a general practice [22], and GPs initiate diagnostics and act as gatekeepers to specialized medical care. Danish GPs are legally bound to keep detailed and contemporaneously updated electronic medical records of their patients.

Study population

We identified all patients aged 18 years or more with an incident diagnosis of cancer, except for non-melanoma skin cancer, during four months (1 May to 31 August 2010). The study population was subsequently restricted to the 73.5% of patients who, according to the GP, had attended general practice as part of the cancer diagnosis (Figure 1). The remaining patients were diagnosed through screening (6.1%), emergency access or as coincidental findings during diagnostics of other illnesses.



Identification of patients

Patients were identified using a validated algorithm [23] that uses data from the Danish National Patient Register (NPR) of all inpatient and outpatient visits and diagnoses defined in accordance with the 10th version of the International Classification of Diseases (ICD-10) [24]. We verified all diagnoses by linking data to the Danish Cancer Registry (DCR) [25]. An incident cancer was defined as having a cancer diagnosis as the primary diagnosis (except for non-melanoma skin cancer) and no prior history of cancer recorded in the DCR (previous non-melanoma skin cancer was allowed).

Data collection

We collected data for each patient by mailing a questionnaire to the patient's GP, who was asked to fill out the questionnaire on the basis of the medical records. The participating GPs received no remuneration. Non-responders received a reminder, including a new questionnaire, after five weeks.

The questionnaire focused on information about the GP's interpretation of the symptoms presented by the patient at the first consultation by asking the GP: 'How did you interpret the symptoms?' The GP was given three possible categories to answer: alarm symptoms suggestive of cancer (alarm), symptoms suggestive of any serious disease (serious), or vague symptoms not directly suggestive of cancer or other serious disease (vague).

Thus, the category of alarm symptoms mirrors the GP's suspicion of cancer. However, the GP's symptom interpretation was subjective and was not based on a pre-specified list of alarm symptoms.

The questionnaire also requested information about the choice of referral for further investigation for cancer, i.e. whether or not a referral was made to a CPP. If no referral to a CPP had been made, the questionnaire focused on information about the patient's referral to specialist care. This enabled us to classify the GP's choice of referral into the following four distinct categories: Cancer Patient Pathway (CPP), cancer obs. pro. but no cancer patient pathway, other, or unknown referral.

We defined the diagnostic interval as the time interval from the date of the patient's first presentation of symptoms in primary care until the date of diagnosis in accordance with the Aarhus Statement [26]. The date of the patient's first presentation of symptoms in primary care was identified by asking the GP the following question: "When did the patient first present to your practice with symptom(s) that you thought were related to the current cancer diagnosis? (date)" [26]. The date of diagnosis was obtained from the DCR; this date corresponds to the date of the first contact (admission date) with the hospital department where the cancer diagnosis was first registered as the primary cause of contact or, if the patient was diagnosed by a private practicing specialist, this date corresponds to the date of the clinical diagnosis

[27]. If the date of diagnosis was missing in the DCR, the admission date from the NPR was used.

Possible confounders considered were gender, age, comorbidity, educational level, disposable income and region of residence. Patient gender and age were derived from the patient's civil registry number (CRN), while citizenship was derived from the Danish Civil Registration System [28]. The patient's complete hospital discharge history (from ten years before the date of the first consultation with the GP) was used to compute a modified Charlson Comorbidity Index (CCI) score in accordance with Quan et al. [29]. We grouped CCI into 'none' (no recorded disease), 'moderate' (index scores of 1 and 2) and 'high' (index scores of 3 or more). We used information on education from Statistics Denmark [30] to identify the educational level of all patients in accordance with the International Standard Classification of Education (ISCED) [31]. We grouped levels of education into 'low' (ISCED levels 1 and 2), 'medium' (ISCED levels 3 and 4) and 'high' (ISCED levels 5 and 6). Finally, the disposable OECD household income level [32] was divided into three categories ('low', 'medium' and 'high') on the basis of data from Statistics Denmark.

More detailed information of identification of patients, data collection and data items are described elsewhere [33].

Ethical approval

The study was approved by the Danish Data Protection Agency (rec. no. 2009-41-3471). The Danish National Board of Health (today the Danish Health and Medicines Authority) gave, according to section 46 of the Danish Health Act, legal permission to obtain information from the GPs' medical records, by questionnaires, without the patients' consent (rec. no. 7-604-04-2/195/EHE). According to Danish law and the Central Denmark Region Committees on Health Research Ethics, approval by the National Committee on Health Research Ethics was not required as no biomedical intervention was performed.

Analyses

We present results for the five most frequent cancers in Denmark (colorectal, lung, malignant melanoma, breast and prostate [34]) and total. Analyses were performed on 3,823 cases with complete data (Figure 1). No imputation of missing data was made. Descriptive analyses were performed using exact non-parametric methods.

We estimated the patients' likelihood to be referred to a CPP as a function of GP symptom interpretation by calculating the prevalence ratios (PRs) using Poisson regression as we expected the outcome to be frequent [35]. The analyses were adjusted for patient gender, age, co-morbidity, educational level, disposable income and region of residence and for patient clusters at GP level.

We estimated the associations between GP symptom interpretation and diagnostic interval and between use of CPP and diagnostic interval using the 'qcount' procedure by Miranda [36] for quantile regression analysis [37] on the smoothed quantiles [38], as we considered the outcome to be count data (discrete). We adjusted for patient gender, age, comorbidity, educational level, disposable income and region of residence. Confidence intervals were calculated using standard errors (SEs) estimated from 1000 repetitions bootstrap.

Statistical significance was set at 0.05 or less, and 95% confidence intervals are shown when appropriate. Analyses were done using Stata® v. 13 (StataCorp LP, College Station, TX, USA).

Results

We identified 7,562 incident cancer patients who fulfilled the inclusion criteria. A total of 5,581 GP questionnaires were returned (response rate: 73.8%). The response rate was higher for female patients, patients diagnosed with breast cancer and patients with high educational level.

The GPs were not involved in diagnosing the cancer for 1,480 (26.5%) of the cases; 343 (6.1%) of these were detected in connection with the national breast cancer screening programme and 1,130 (20.4%) were detected otherwise. Patients listed with uninvolved GPs were more likely to be women, to be 55–64 years of age, to have higher 1-year survival and to have medium educational level.

We excluded 278 (6.8%) patients due to missing information on three main variables: dates (125 patients (3.0%)), use of CPP (7 patients (0.2%)) and GP's symptom interpretation (146 patients (3.6%)) (Figure 1). The excluded patients were more likely to be diagnosed with prostate cancer or colorectal cancer, to have moderate co-morbidity, to be over 75 years of age and to have distant tumour stage (metastatic cancer).

The analysed patient group thus consisted of 3,823 patients of which 53.3% were males, and 52.5% were 55–74 years of age (Table 1).

Cancer suspicion and use of CPPs

In 48.2% of the cases, the GP interpreted the patient's symptom as an 'alarm' symptom. This ranged from 31.2% for lung cancer patients to 80.9% for breast cancer patients (Table 1). The GP used CPPs in 1,426 (37.3%) of all cases, ranging from 36.1% for malignant melanoma patients to 62.5% for breast cancer patients (Table 1). The GP used CPPs in 52.0% of the cases, who had symptoms interpreted to be 'alarm' symptoms with variation among the different cancer sites (Table 2).

Referral to a CPP was more likely among male patients than among female patients (PR = 1.12 (95% CI: 1.00–1.24)). Referral to a CPP was less likely among patients,

Table 1 Characteristics of included patients for whom the GP was involved in the clinical pathway, shown by cancer site and total (N = 3,823)

	Colorectal	Lung	Malignant melanoma	Breast	Prostate	Other	Total
	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
All	612(100)	474(100)	227(100)	518(100)	556(100)	1,436(100)	3,823(100)
Gender							
Male	325(53.1)	266(56.1)	100(44.1)	0(0)	556(100)	790(55.0)	2,037(53.3)
Female	287(46.9)	208(43.9)	127(55.9)	518(100)	0(0)	646(45.0)	1,786(46.7)
Age groups (years):							
18-44	16(2.6)	3(0.6)	63(27.8)	69(13.3)	0(0)	146(10.2)	297(7.8)
45-54	46(7.5)	42(8.9)	48(21.1)	119(23.0)	20(3.6)	184(12.8)	459(12.0)
55-64	115(18.8)	136(28.7)	43(18.9)	100(19.3)	136(24.5)	325(22.6)	855(22.4)
65-74	219(35.8)	167(35.2)	36(15.9)	91(17.6)	238(42.8)	400(27.9)	1,151(30.1)
> = 75	216(35.3)	126(26.6)	37(16.3)	139(26.8)	162(29.1)	381(26.5)	1,061(27.8)
GP's symptom interpretation							
Alarm	298(48.7)	148(31.2)	121(53.3)	419(80.9)	264(47.5)	592(41.2)	1,842(48.2)
Serious	127(20.8)	162(34.2)	9(4.0)	27(5.2)	59(10.6)	362(25.2)	746(19.5)
Vague	187(30.6)	164(34.6)	97(42.7)	72(13.9)	233(41.9)	482(33.6)	1,235(32.3)
Referral mode							
Cancer Patient Pathway (CPP)	222(36.3)	193(40.7)	82(36.1)	324(62.5)	220(39.6)	385(26.8)	1,426(37.3)
Cancer obs – no CPP	108(17.6)	79(16.7)	76(33.5)	92(17.8)	199(35.8)	369(25.7)	923(24.1)
Other	262(42.8)	174(36.7)	61(26.9)	83(16.0)	114(20.5)	613(42.7)	1,307(34.2)
Unknown	20(3.3)	28(5.9)	8(3.5)	19(3.7)	23(4.1)	69(4.8)	167(4.4)
Co-morbidity¹							
None	453(74.0)	323(68.1)	192(84.6)	406(78.4)	422(75.9)	1,088(75.8)	2,884(75.4)
Moderate	132(21.6)	124(26.2)	33(14.5)	93(18.0)	114(20.5)	286(19.9)	782(20.5)
High	27(4.4)	27(5.7)	2(0.9)	19(3.7)	20(3.6)	62(4.3)	157(4.1)
Missing	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)
Educational level – ISCED²							
Low	237(38.7)	211(44.5)	61(26.9)	179(34.6)	182(32.7)	551(38.4)	1,421(37.2)
Medium	230(37.6)	170(35.9)	93(41.0)	202(39.0)	236(42.4)	558(38.9)	1,489(38.9)
High	112(18.3)	73(15.4)	67(29.5)	121(23.4)	126(22.7)	263(18.3)	762(19.9)
Missing	33(5.4)	20(4.2)	6(2.6)	16(3.1)	12(2.2)	64(4.5)	151(3.9)
Disposable income in euro – OECD³							
Low	233(38.1)	198(41.8)	50(22.0)	150(29.0)	138(24.8)	494(34.4)	1,263(33.0)
Medium	209(34.2)	161(34.0)	73(32.2)	184(35.5)	194(34.9)	481(33.5)	1,302(34.1)
High	169(27.6)	115(24.3)	103(45.4)	183(35.3)	224(40.3)	460(32.0)	1,254(32.8)
Missing	1(0.2)	0(0)	1(0.4)	1(0.2)	0(0)	1(0.1)	4(0.1)
Region of residence⁴							
North Denmark Region	61(10.0)	43(9.1)	24(10.6)	60(11.6)	81(14.6)	178(12.4)	447(11.7)
Central Denmark Region	141(23.0)	120(25.3)	48(21.1)	129(24.9)	148(26.6)	343(23.9)	929(24.3)
Region of Southern Denmark	139(22.7)	101(21.3)	86(37.9)	128(24.7)	112(20.1)	321(22.4)	887(23.2)
Capital Region of Denmark	142(23.2)	128(27.0)	53(23.3)	109(21.0)	130(23.4)	359(25.0)	921(24.1)
Region Zealand	129(21.1)	82(17.3)	16(7.0)	92(17.8)	85(15.3)	235(16.4)	639(16.7)

¹Charlson's Comorbidity index, ²ISCED = International Standard Classification of Education, ³Disposable income (in thousand of euro according to OECD classification, ⁴Region of the patient's GP as of November 2010.

Table 2 Number and percentages of Cancer Patient Pathways (CPP) used among patients for whom the GP was involved in the diagnosis, shown by cancer site and total (N = 1,426)

	Colorectal n(%)	Lung n(%)	Malignant melanoma n(%)	Breast n(%)	Prostate n(%)	Other n(%)	Total n(%)
Total	222(36.3)	193(40.7)	82(36.1)	324(62.5)	220(39.6)	385(26.8)	1,426(37.3)
Gender							
Male	130(40.0)	110(41.4)	38(38.0)	0(0)	220(39.6)	230(29.1)	728(35.7)
Female	92(32.1)	83(39.9)	44(34.6)	324(62.5)	0(0)	155(24.0)	698(39.1)
Age groups(years):							
18-44	6(37.5)	1(33.3)	22(34.9)	37(53.6)	0(0)	39(26.7)	105(35.4)
45-54	12(26.1)	13(31.0)	15(31.3)	67(56.3)	10(50.0)	53(28.8)	170(37.0)
55-64	50(43.5)	58(42.6)	20(46.5)	62(62.0)	58(42.6)	87(26.8)	335(39.2)
65-74	82(37.4)	74(44.3)	14(38.9)	55(60.4)	104(43.7)	102(25.5)	431(37.4)
> = 75	72(33.3)	47(37.3)	11(29.7)	103(74.1)	48(29.6)	104(27.3)	385(36.3)
GP's symptom Interpretation							
Alarm	163(54.7)	74(50.0)	51(42.1)	305(72.8)	121(45.8)	243(41.0)	957(52.0)
Serious	17(13.4)	52(32.1)	0(0)	5(18.5)	20(33.9)	55(15.2)	149(20.0)
Vague	42(22.5)	67(40.9)	31(32.0)	14(19.4)	79(33.9)	87(18.0)	320(25.9)

who had symptoms interpreted to be vague symptoms (Table 3). Only the GP's symptom interpretation remained statistically significant associated with CPP referral, across cancer sites, after adjustments, except for malignant melanoma for which no association was found (Table 3). Furthermore, even though no overall association between age and CPP referral was observed, breast cancer patients aged 45–64 were less likely to be referred to a CPP (Table 3).

Diagnostic interval

The overall median diagnostic interval was 32 days (interquartile interval (IQI): 14–73) and varied from a median of 18 (IQI: 8–34) days for breast cancer patients to a median of 46 (IQI: 21–110) days for prostate cancer patients ($p < 0.001$). The diagnostic interval differed statistically significantly between GP symptom interpretation ($p < 0.001$) and GP referral modes ($p < 0.001$) (Table 4).

The adjusted diagnostic interval was longer when the GP did not suspect cancer and also when the GP did not refer to a CPP. Symptoms interpreted as 'Vague' displayed the strongest association with the diagnostic interval, ranging from an additional 17 (95% CI: 13;21) days at the 25th percentile to an additional 192 (95% CI: -98;483) days at the 90th percentile compared to patients, who had symptoms interpreted to be alarm symptoms (Table 5). The additional diagnostic interval that was associated with GP's interpretation of symptoms as 'vague' was approximately twice as long as the additional diagnostic interval that was associated with non-CPP referral (Table 5).

Discussion

The GPs suspected cancer in 48.2% of all cancer patients and initiated CPP in 37.2% of all cases. Patients had a lower likelihood to be referred to a CPP if the GP interpreted symptoms as 'vague' or 'serious' compared to 'alarm' symptoms. Thus, the GP's symptom interpretation increased the diagnostic interval for the group interpreted to have 'vague' symptoms (32.7% of all cases) and the group interpreted to have 'serious' symptoms (19.2% of all cases).

The GP's symptom interpretation influenced the diagnostic interval twice as much as the referral mode chosen by the GP. This indicates that the GP-assessed severity of symptoms influences the diagnostic interval more than the GP's choice of referral mode.

Strengths and weaknesses of the study

The size of this study is a major strength as the considerable data ensure high statistical precision. Furthermore, the study population was well-defined and complete with minimal selection bias as all cases were identified through the NPR [23,33], wherein 98% of all cancer patients in Denmark are registered [25]. Yet, we may have missed some patients due to delay in NPR registrations. However, this is expected to be negligible as we performed consecutive sampling (including late-registered patients) [23].

The high response rate of 74% further reduces the risk of selection bias. The small differences in gender for patients listed with responding and non-responding GPs should not affect the representativeness of the study as the cohort resembles patients in the Danish Cancer

Table 3 Patient's chance of CPP referral initiated by the GP, expressed as adjusted prevalence ratios (PRs) by cancer site and total (N=3,672)

	Colorectal	Lung	Malignant melanoma	Breast	Prostate	Other	Total
	PRR (95% CI)	PRR (95% CI)	PRR (95% CI)	PRR (95% CI)	PRR (95% CI)	PRR (95% CI)	PRR (95% CI)
Gender							
Male	1.08(0.88-1.32)	1.02(0.81-1.27)	1.02(0.72-1.44)	n/a	1.00	1.22(1.03-1.44)	1.12(1.00-1.24)
Female	1.00(ref)	1.00(ref)	1.00(ref)	1.00	n/a	1.00(ref)	1.00(ref)
Age groups (years):							
18-44	1.67(0.87-3.18)	0.64(0.09-4.32)	1.16(0.60-2.21)	0.86(0.69-1.09)	-	0.98(0.71-1.34)	1.04(0.88-1.24)
45-54	1.02(0.63-1.66)	0.72(0.43-1.22)	1.09(0.54-2.19)	0.78(0.64-0.96)	1.70(0.98-2.93)	1.04(0.78-1.39)	0.97(0.84-1.12)
55-64	1.49(1.11-2.00)	0.94(0.68-1.29)	1.69(0.88-3.26)	0.80(0.65-1.00)	1.33(0.96-1.83)	1.05(0.82-1.36)	1.11(0.98-1.26)
65-74	1.18(0.91-1.54)	1.09(0.83-1.42)	1.39(0.72-2.68)	0.88(0.72-1.07)	1.38(1.04-1.84)	0.92(0.72-1.17)	1.06(0.95-1.18)
> = 75	1.00(ref)	1.00(ref)	1.00(ref)	1.00(ref)	1.00(ref)	1.00(ref)	1(ref)
GP's symptom interpretation							
Alarm	1.00(ref)	1.00(ref)	1.00(ref)	1.00(ref)	1.00(ref)	1.00(ref)	1.00(ref)
Serious	0.27(0.17-0.41)	0.64(0.49-0.85)	n/a	0.23(0.09-0.56)	0.71(0.47-1.06)	0.34(0.26-0.45)	0.40(0.34-0.48)
Vague	0.40(0.30-0.54)	0.83(0.65-1.05)	0.76(0.52-1.13)	0.27(0.17-0.43)	0.72(0.58-0.90)	0.44(0.35-0.55)	0.53(0.48-0.60)

Adjusted for the patient's gender, age, co-morbidity, educational background and disposable income, cancer site and patient clusters at GP level.

Estimates marked in bold were statistically significant at minimum level of $p < 0.05$.

n/a = not applicable.

Table 4 Unadjusted median diagnostic intervals (DIs) with inter-quartile intervals (IQI) displayed for five high incidence cancer sites and totally (N=3,823)

	Colorectal	Lung	Malignant melanoma	Breast	Prostate	Other	Total
	Median (IQI)	Median (IQI)	Median (IQI)	Median (IQI)	Median (IQI)	Median (IQI)	Median (IQI)
Total	31(14;69)	28(11;67)	28(12;55)	18(8;34)	46(21;110)	40(16;88)	32(14;73)
Gender							
Male	28 (13;64)	27(9;67)	22(9;53)	n/a	46(21;110)	38(15;84)	35 (14;81)
Female	35 (16;73)	28(13;69)	30(15;56)	18(8;34)	n/a	43(17;90)	29 (12;63)
Age groups (years):							
18-44	44(31;89)	68 (13;96)	31(11;55)	19(11;30)	n/a	45(15;116)	30 (13;72)
45-54	31(16;61)	18 (11;35)	23(12;45)	22(8;36)	47(25;160)	35(16;73)	27 (13;54)
55-64	28(11;67)	25 (8;44)	24(11;45)	15(6;32)	36(22;105)	38(15;77)	30 (13;64)
65-74	30(14;61)	27 (9;77)	30(15;56)	21(9;36)	46(22;97)	41(17;90)	35 (15;78)
> = 75	34(15;83)	33 (14;87)	36(14;68)	14(7;30)	53(17;165)	42(14;94)	34 (13;84)
GP's symptom Interpretation							
Alarm	21 (8;41)	15 (7;36)	16 (6;35)	15 (7;28)	36 (15;84)	25 (10;51)	21 (8;42)
Serious	31 (16;65)	27 (9;65)	n/a	29 (12;55)	42 (25;88)	35 (15;74)	33 (14;72)
Vague	61 (30;142)	44 (21;89)	39 (23;78)	44 (24;66)	59 (24;177)	75 (38;152)	60 (28;127)
Referral mode							
Cancer Patient Pathway (CPP)	22 (8;46)	20 (9;46)	15 (6;29)	13 (5;23)	34 (19;75)	29 (11;56)	22 (8;44)
Cancer obs – no CPP	29 (14;67)	29 (12;65)	26 (12;45)	28 (13;43)	43 (21;154)	40 (15;79)	34 (14;75)
Other	42 (21;85)	37 (14;89)	56 (36;87)	32 (18;54)	67 (29;165)	51 (22;116)	49 (21;99)
Unknown	34 (10;75)	29 (7;69)	20 (8;45)	39 (17;77)	47 (13;505)	36 (13;98)	33 (12;93)

Estimates marked in bold were statistically significant at minimum level of $p < 0.05$.
n/a = not applicable.

Registry [23]. However, patients who were excluded due to GP non-response may have had longer diagnostic intervals than the included patients. However, this will give minimal bias (if any) as we looked at associations between diagnostic interval and symptom presentation.

Information bias caused by GP recall bias was reduced as we used the GPs' contemporaneously updated electronic medical records. Even so, the retrospective nature of the questionnaire may imply the risk that some of the GPs may have misinterpreted the symptoms of a particular case and hence may have overestimated the proportion of cases with 'alarm' symptoms. This would tend to underestimate the association between the GP's assessment of 'alarm-symptoms', use of CPPs and the diagnostic interval. Yet, we believe that this cannot fully explain the proportion of patients with 'alarm' symptoms found in our study as other studies have found similar proportions [19,20].

Information bias due to use of 'date of first contact' as 'date of diagnosis' would tend to underestimate the length of the diagnostic interval by setting an earlier date

of diagnosis. We consider this to be non-differential as this is suspected to be the case for all subgroups and hence will not depend on the GPs symptom interpretation and choice of referral route. Yet, it could be argued that this information bias would be stronger for patients who were not referred to a CPP as these have longer intervals (and thus may have a relatively higher impact on non-CPP patients). If this is the case, this could lead to an underestimation of the differences between referral groups, and the observed differences would thus represent minimum estimates of the true differences.

Comparison with other findings

Our finding that nearly 50% of cancer patients, who had symptoms interpreted to be 'alarm' symptoms of cancer prior to a cancer diagnosis represent a slightly higher number than the previously reported 40% [19,20]. Yet, this suggests that half of all cancer patients present without an 'alarm' symptom of cancer. In combination with the fact that most symptoms of cancer are highly prevalent in general practice [16,19,20], this indicates that a

Table 5 Diagnostic interval in calendar days displayed by GP's symptom interpretation, referral mode, gender, age groups and co-morbidity (N=3,672)

	n (%)	Quantile regression results (adjusted) ¹			
		25th percentile estimate (95% CI)	50th percentile estimate (95% CI)	75th percentile estimate (95% CI)	90th percentile estimate (95% CI)
Gender					
Male	1,961 (53.4)	-4 (-6;-1)	-1(-6;3)	-6(-21;10)	-19(-242;203)
Female	1,711 (46.6)	ref.	ref.	ref.	ref.
Age groups (years):					
18-44	289 (7.9)	-1(-7;4)	-1(-9;4)	-8(-22;7)	-52(-139;35)
45-54	447 (12.2)	-2(-6;2)	-6(-12;0)	-10(-25;5)	-37(-276;303)
55-64	835 (22.7)	-3 (-6;0)	-5(-10;1)	-11(-29;7)	-56(-132;21)
65-74	1,129 (30.7)	0(-2;2)	0(-6;6)	-2(-21;17)	-30(-107;48)
> = 75	972 (26.5)	ref.	ref.	ref.	ref.
GP's symptom Interpretation					
Alarm	1,766 (48.1)	ref.	ref.	ref.	ref.
Serious	706 (19.2)	3 (0;6)	8 (3;13)	24 (7;41)	68(-102;237)
Vague	1,200 (32.7)	17 (13;21)	34 (28;41)	72 (38;107)	192(-98;483)
Referral Mode					
CPP	1,371 (37.3)	ref.	ref.	ref.	ref.
Cancer obs. - no CPP	888 (24.2)	5 (1;9)	13 (7;19)	32 (17;46)	108(-31;248)
Other reasons	1,253 (34.1)	8 (4;11)	16 (11;22)	34 (17;52)	123(86;331)
Unknown	160 (4.4)	3(-7;13)	10(-10;30)	30 (1;59)	179(-412;770)
Co-morbidity					
None	2,780 (75.7)	ref.	ref.	ref.	ref.
Moderate	741 (20.2)	-1(-3;1)	2(-2;7)	8(-6;23)	5(-57;66)
High	151 (4.1)	-2(-7;4)	1(-9;13)	-1(-30;28)	-27(-110;55)

Point estimates marked in bold are statistically significant at minimum level of $p < 0.05$.

¹Adjusted for gender, age groups, symptom interpretation, referral mode, cancer site, comorbidity, educational background, disposable income and region of residence.

patient may have cancer even if no specific alarm symptoms are presented by the patient.

Our study is the first to document the use of CPP in primary care for all cancers in Denmark. Our finding that approximately one-third of all patients are referred to a CPP is comparable to the findings on the use of 2WW in the UK [8-10,13,39]. The reasons for these results remain unknown, but it may be suspected that the criteria behind the 'reasonable suspicion of cancer', is too specific to target the patients' symptomatology in general practice, as up to 60% of cancer patients do not present with alarm symptoms [19,20]. This issue has also been raised as a concern in the UK [8,13].

To our knowledge, only one study has estimated adjusted associations with the diagnostic interval at different percentiles, but this study did not adjust for cancer suspicion nor for the case-mix [40]. Hence, our study is the first to quantify the associations between cancer suspicion and diagnostic interval at different percentiles while also accounting for the case-mix. Even so, our

finding of an overall (unadjusted) median diagnostic interval of one month is similar to the findings of other studies [8,11,12,40-42].

The low use of CPP referrals in combination with a longer diagnostic interval for patients, whose symptoms was not interpreted as 'alarm' symptoms make us question if the CPP (and 2WW) approach to faster diagnosis is the optimal method to use at the starting point of the diagnostic trajectory. In fact, we have shown that lack of cancer suspicion by the GP decreases the likelihood of CPP referral and influences the diagnostic interval considerably more than the actual use of CPP, in particular among patients with vague symptoms.

We have also shown that the severity of presented symptoms was not directly associated with the GP's use of a fast-track system. In combination with the English data that a 'fast-track' system may disadvantage the large group of patients without a warning sign of cancer [10,13], our finding may be interpreted as a demonstration of the possible fallacies of the CPP and 2WW

referral routes for cancer and why an additional approach with quick and easy access to all initial investigations ordered by a GP to qualify the possibility of cancer may be needed, but further research into the organisation of rational investigations is highly needed.

Clinical implications

This study underlines the importance for clinicians in general practice to consider and investigate for cancer even when the patient does not present well-known alarm symptoms of cancer. Otherwise, only a proportion of cancer patients will be provided the faster diagnostic pathway, leaving approximately half of all cancer patients to a longer period of uncertainty before diagnosis is confirmed. This implies that the GPs must have access to relevant investigations if the aim is to achieve earlier cancer diagnosis.

Conclusions

GPs suspected cancer more often than they initiated a CPP, and patients were less likely to be referred to a CPP if their symptoms were not interpreted to be an 'alarm' symptom of cancer. Furthermore, when the patient's symptoms were interpreted by the GP as 'vague', this gave rise to a significantly prolonged diagnostic interval; the impact of the symptom interpretation was approximately twice that of not using CPP referral routes. To decrease the time from first symptom presentation until diagnosis for those without alarm symptoms, GPs may need additional routes other than the fast-track routes.

Abbreviations

CPP: Standardised Cancer Patient Pathways; GP: General practitioner; PR: Prevalence Ratio; 2WW: 2 Week Wait; NPR: Danish National Patient Registry; DCR: Danish Cancer Register; CRN: Danish Civil Registration Number; CCI: Charlson Co-morbidity Index; ISCED: International Standard Classification of Education.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

HJ was involved in the initial conception of the study, participated in its design, performed the statistical analyses and drafted the manuscript. MLT, FO and PV all contributed to the conception, development and design of the study and provided critical revision of the intellectual contents of the manuscript. JO provided critical revision of the intellectual contents of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank data manager Kaare Rud Flarup for his outstanding and meticulous help in setting up and maintaining the database and to enable register linkage with Statistics Denmark. We would also like to thank Statistics Denmark for providing the it-infrastructure of registries, which made this study possible.

Funding

This study was funded by the Health Foundation (Helsefonden) [2012B123], the Tryg Foundation (Trygfonden) [7-12-0958] and the Central Denmark

Region Foundation for Primary Health Care Research (Praksisforskningsfonden) [1-15-1-72-13-09].

Author details

¹Research Unit for General Practice, Research Centre for Cancer Diagnosis in Primary Care, Department of Public Health, Aarhus University, Bartholins Allé 2, DK-8000 Aarhus C, Denmark. ²Section for General Medical Practice, Department of Public Health, Aarhus University, Bartholins Allé 2, DK-8000 Aarhus C, Denmark. ³Department of Experimental Clinical Oncology, Aarhus University Hospital, Noerrebrogade, DK-8000 Aarhus C, Denmark.

Received: 27 May 2014 Accepted: 26 August 2014
Published: 30 August 2014

References

1. Prades J, Espinas JA, Font R, Argimon JM, Borrás JM: **Implementing a Cancer Fast-track Programme between primary and specialised care in Catalonia (Spain): a mixed methods study.** *Br J Cancer* 2011, **105**:753–759.
2. Probst HB, Hussain ZB, Andersen O: **Cancer patient pathways in Denmark as a joint effort between bureaucrats, health professionals and politicians-A national Danish project.** *Health Policy* 2012, **105**:65–70.
3. Olesen F, Hansen RP, Vedsted P: **Delay in diagnosis: the experience in Denmark.** *Br J Cancer* 2009, **101**:S5–S8.
4. Toustrup K, Lambertsen K, Birke-Sorensen H, Ulhøi B, Sorensen L, Grau C: **Reduction in waiting time for diagnosis and treatment of head and neck cancer - a fast track study.** *Acta Oncol* 2011, **50**:636–641.
5. Vallverdu-Cartie H, Comajuncosas-Camp J, Orbeal-Saenz RA, Lopez-Negre JL, Gris Garriga PJ, Jimeno-Fraile J, Hermoso-Bosch J, Sanchez-Pradell C, Torra-Alsina S, Urgelles-Bosch J, Pares D: **Results of implementation of a fast track pathway for diagnosis of colorectal cancer.** *Rev Esp Enferm Dig* 2011, **103**:402–407.
6. Valentin-Lopez B, Ferrandiz-Santos J, Blasco-Amaro JA, Morillas-Sainz JD, Ruiz-Lopez P: **Assessment of a rapid referral pathway for suspected colorectal cancer in Madrid.** *Fam Pract* 2012, **29**:182–188.
7. Department of Health: *The NHS Cancer Plan. A plan for investment, A plan for reform.* London: Department of Health; 2000.
8. Baughan P, O'Neill B, Fletcher E: **Auditing the diagnosis of cancer in primary care: the experience in Scotland.** *Br J Cancer* 2009, **101**(2):S87–S91.
9. Potter S, Govindarajulu S, Shere M, Braddon F, Curran G, Greenwood R, Sahu AK, Cawthorn SJ: **Referral patterns, cancer diagnoses, and waiting times after introduction of two week wait rule for breast cancer: prospective cohort study.** *BMJ* 2007, **335**:288.
10. Jones R, Rubin G, Hungin P: **Is the two week rule for cancer referrals working?** *BMJ* 2001, **322**:1555–1556.
11. Neal RD, Allgar VL, Ali N, Leese B, Heywood P, Proctor G, Evans J: **Stage, survival and delays in lung, colorectal, prostate and ovarian cancer: comparison between diagnostic routes.** *Br J Gen Pract* 2007, **57**:212–219.
12. Elliss-Brookes L, McPhail S, Ives A, Greenslade M, Shelton J, Hiom S, Richards M: **Routes to diagnosis for cancer - determining the patient journey using multiple routine data sets.** *Br J Cancer* 2012, **107**:1220–1226.
13. Allgar VL, Neal RD, Ali N, Leese B, Heywood P, Proctor G, Evans J: **Urgent GP referrals for suspected lung, colorectal, prostate and ovarian cancer.** *Br J Gen Pract* 2006, **56**:355–362.
14. The National Board of Health: *National Cancer Plan II - Denmark National Board of Health recommendations for improving cancer healthcare services.* Copenhagen: The National Board of Health; 2005.
15. Svendsen RP, Stovring H, Hansen BL, Kragstrup J, Sondergaard J, Jarbol DE: **Prevalence of cancer alarm symptoms: A population-based cross-sectional study.** *Scand J Prim Health Care* 2010, **28**:132–137.
16. Jones R, Charlton J, Latinovic R, Gulliford M: **Alarm symptoms and identification of non-cancer diagnoses in primary care: cohort study.** *BMJ* 2009, **339**:1–9.
17. Jones R, Latinovic R, Charlton J, Gulliford MC: **Alarm symptoms in early diagnosis of cancer in primary care: cohort study using General Practice Research Database.** *BMJ* 2007, **334**:1040.
18. Neal RD, Din NU, Hamilton W, Ukoumunne OC, Carter B, Stapley S, Rubin G: **Comparison of cancer diagnostic intervals before and after implementation of NICE guidelines: analysis of data from the UK General Practice Research Database.** *Br J Cancer* 2014, **110**:584–592.

19. Scheel BI, Ingebrigtsen SG, Thorsen T, Holtedahl K: **Cancer suspicion in general practice: the role of symptoms and patient characteristics, and their association with subsequent cancer.** *Br J Gen Pract* 2013, **63**:627–635.
20. Ingebrigtsen SG, Scheel BI, Hart B, Thorsen T, Holtedahl K: **Frequency of 'warning signs of cancer' in Norwegian general practice, with prospective recording of subsequent cancer.** *Fam Pract* 2013, **30**:153–160.
21. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: *GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10.* Lyon: International Agency for Research on Cancer; 2012.
22. Andersen JS, Olivarius NF, Krasnik A: **The Danish National Health Service Register.** *Scand J Public Health* 2011, **39**:34–37.
23. Larsen MB, Jensen H, Hansen RP, Olesen F, Vedsted P: **Identification of patients with incident cancers using administrative registry data.** *Dan Med J* 2014, **61**:A4777.
24. Lynge E, Sandegaard JL, Rebolj M: **The Danish National Patient Register.** *Scand J Public Health* 2011, **39**:30–33.
25. Gjerstorff ML: **The Danish Cancer Registry.** *Scand J Public Health* 2011, **39**:42–45.
26. Weller D, Vedsted P, Rubin G, Walter FM, Emery J, Scott S, Campbell C, Andersen RS, Hamilton W, Olesen F, Rose P, Nafees S, van Rijswijk E, Hiom S, Muth C, Beyer M, Neal RD: **The Aarhus statement: improving design and reporting of studies on early cancer diagnosis.** *Br J Cancer* 2012, **106**:1262–1267.
27. The National Board of Health: *Det moderniserede Cancerregister - metode og kvalitet [In Danish].* Copenhagen: The National Board of Health; 2009.
28. Pedersen CB: **The Danish Civil Registration System.** *Scand J Public Health* 2011, **39**:22–25.
29. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V: **Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.** *Am J Epidemiol* 2011, **173**:676–682.
30. Thygesen LC, Daasnes C, Thaulow I, Bronnum-Hansen H: **Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving.** *Scand J Public Health* 2011, **39**:12–16.
31. UNESCO: *International Standard Classification of Education ISCED 2011.* Montreal, Quebec, Canada: UNESCO; 2012.
32. Statistics Denmark: **Quality Declarations.** In <http://dst.dk/en/Statistik/dokumentation/Declarations.aspx>.
33. Jensen H, Topping ML, Larsen MB, Vedsted P: **Existing data sources for clinical epidemiology: Danish Cancer in Primary Care (CaP) cohort.** *Clin Epidemiol* 2014, **6**:237–246.
34. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F: **Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.** *Eur J Cancer* 2013, **49**:1374–1403.
35. Barros AJ, Hirakata VN: **Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio.** *BMC Med Res Methodol* 2003, **3**:21.
36. Miranda A: *QCOUNT: Stata program to fit quantile regression models for count data.* Boston: Boston College Department of Economics; 2006.
37. Hao N: *Quantile regression.* Thousand Oaks, Calif: Sage Publications; 2007.
38. Machado JA, Santos Silva JMC: **Quantiles for Counts.** *J Am Stat Assoc* 2005, **100**:1225–1237.
39. Davies RJ, Ewings P, Welbourn R, Collins C, Kennedy R, Royle C: **A prospective study to assess the implementation of a fast-track system to meet the two-week target for colorectal cancer in Somerset.** *Colorectal Dis* 2002, **4**:28–30.
40. Dwivedi AK, Dwivedi SN, Deo S, Shukla R, Pandey A, Dwivedi DK: **An Epidemiological study on delay in treatment initiation of cancer patients.** *Health* 2012, **4**:66–79.
41. Hansen RP, Vedsted P, Sokolowski I, Sondergaard J, Olesen F: **Time intervals from first symptom to treatment of cancer: a cohort study of 2,212 newly diagnosed cancer patients.** *BMC Health Serv Res* 2011, **11**:284.
42. Murchie P, Campbell NC, Delaney EK, Dinant GJ, Hannaford PC, Johansson L, Lee AJ, Rollano P, Spigt M: **Comparing diagnostic delay in cancer: a cross-sectional study in three European countries with primary care-led health care systems.** *Fam Pract* 2012, **29**:69–78.

doi:10.1186/1471-2407-14-636

Cite this article as: Jensen et al.: Cancer suspicion in general practice, urgent referral and time to diagnosis: a population-based GP survey and registry study. *BMC Cancer* 2014 **14**:636.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

